FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ı	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burde	en							
l	hours per response:	0.5							

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  REED JOHN C					2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
KEED JUHN C													r		10% Ow	ner		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2008							Officer below)	(give title		Other (s below)	pecify		
C/O ISIS PHARMACEUTICALS, INC.																		
1896 RUTHERFORD ROAD						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													led by One	Repo	rting Person			
CARLSBAD CA 92008		92008	_							Form filed by More than One Reporting Person								
(City)	(S	tate)	(Zip)															
		Tal	ole I - Non-De		_			cquired, Di				1						
1. Title of Security (Instr. 3)  2. Transa Date (Month/D.					action 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Instr.   5)			d (A) or r. 3, 4 and	5. Amour Securitie Beneficia Owned F	es Form ally (D) o following (I) (Ir		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)			
			Table II - Deri (e.g.					uired, Disp s, options,				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Ye		Execution Date,		4. Transaction Code (Instr. 8)		ve es d ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Director Stock Option (right to buy)	\$13.88	07/01/2008	07/01/2008	A		15,000		07/01/2009 <sup>(1)</sup>	06/30/2018	Common Stock	15,000	\$0	15,000		D			

## **Explanation of Responses:**

1. Grant of 7-1-08 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, with the first installment vesting on 7-1-09. The option shall be fully vested and exercisable on 7-1-12. The option is exercisable as to 0 shares on 7-1-08.

## Remarks:

/s/B. Lynne Parshall, Attorneyin-Fact 07/01/2008

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.